Trials / Completed
CompletedNCT00722501
Study Evaluating the Safety and Pharmacokinetics of Ascending Single IV Doses of ERB-257
Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ERB-257 Administered Intravenously as a 30-Minute Infusion to Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ascending single IV doses of ERB-257 in healthy subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ERB-257 | |
| OTHER | placebo |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2008-07-25
- Last updated
- 2009-04-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00722501. Inclusion in this directory is not an endorsement.